Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data

OGphoto/iStock via Getty Images Thesis Lyell Immunopharma ( LYEL ) stock has been on a very bullish run this year. The stock is up 191% year to date and is still showing good momentum going into 2026. Whilst the company won't be generating OGphoto/iStock via Getty Images Lyell Immunopharma ( LYEL ) stock has been on a very bullish run this year. The stock is up 191% year to date and is still showing good momentum going into 2026. Whilst the company won't be generating Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Preview: ~241 words